ORIC Pharma partners with Pfizer on ORIC-533 Phase 2 combo study; Pfizer invests $25M

Oric Pharmaceuticals, Inc.

Pfizer to invest $25M for 5,376,344 shares at $4.65/share in registered direct offering.
ORIC and Pfizer will conduct a Phase 2 study of ORIC-533 combined with elranatamab in multiple myeloma.
Jeff Settleman, Pfizer Oncology CSO, joins ORIC's Scientific Advisory Board.
ORIC retains full ownership of ORIC-533; net proceeds extend cash runway into 1H 2025.
Offering expected to close Dec 23, 2022; no underwriter or placement agent involved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.